Opko Health Inc. (Nasdaq: OPK) reported disappointing results from a Phase 3 clinical study of hGH-CTP in growth hormone deficient adults sending the stock price plummeting $2.16 to close at $9.30.
Opko Health disappoints
December 30, 2016 at 17:20 PM EST